請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73867
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡孟勳 | |
dc.contributor.author | Wen-Chun Lin | en |
dc.contributor.author | 林玟君 | zh_TW |
dc.date.accessioned | 2021-06-17T08:12:19Z | - |
dc.date.available | 2019-08-18 | |
dc.date.copyright | 2019-08-18 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-15 | |
dc.identifier.citation | 1. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394- 424.
2. Pera, M. and M. Pera, Recent changes in the epidemiology of esophageal cancer. Surg Oncol, 2001. 10(3): p. 81-90. 3. Pakzad, R., et al., The incidence and mortality of esophageal cancer and their relationship to development in Asia. Ann Transl Med, 2016. 4(2): p. 29. 4. Zhang, Y., Epidemiology of esophageal cancer. World J Gastroenterol, 2013. 19(34): p. 5598-606. 5. Abbas, G. and M. Krasna, Overview of esophageal cancer. Ann Cardiothorac Surg, 2017. 6(2): p. 131-136. 6. Short, M.W., K.G. Burgers, and V.T. Fry, Esophageal Cancer. Am Fam Physician, 2017. 95(1): p. 22-28. 7. Huang, F.L. and S.J. Yu, Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg, 2018. 41(3): p. 210-215. 8. Liu, J., et al., Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg, 2012. 41(3): p. e7-11. 9. Mansour, N.M., S.S. Groth, and S. Anandasabapathy, Esophageal Adenocarcinoma: Screening, Surveillance, and Management. Annu Rev Med, 2017. 68: p. 213-227. 10. Shaheen, N.J. and J.E. Richter, Barrett's oesophagus. Lancet, 2009. 373(9666): p. 850-61. 11. Reid, B.J., et al., Barrett's esophagus: ordering the events that lead to cancer. Eur J Cancer Prev, 1996. 5 Suppl 2: p. 57-65. 12. Schoofs, N., R. Bisschops, and H. Prenen, Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview. Ann Gastroenterol, 2017. 30(1): p. 1-6. 13. Jankowski, J.A., et al., Molecular evolution of the metaplasia-dysplasia- adenocarcinoma sequence in the esophagus. Am J Pathol, 1999. 154(4): p. 965-73. 14. Munitiz, V., et al., High risk of malignancy in familial Barrett's esophagus: presentation of one family. J Clin Gastroenterol, 2008. 42(7): p. 806-9. 15. Gupta, M., et al., Barrett esophagus with progression to adenocarcinoma in multiple family members with attenuated familial polyposis. Gastroenterol Hepatol (N Y), 2011. 7(5): p. 340-2. 16. Yoshida, N., Inflammation and oxidative stress in gastroesophageal reflux disease. J Clin Biochem Nutr, 2007. 40(1): p. 13-23. 17. Chen, H., et al., Molecular mechanisms of Barrett's esophagus. Dig Dis Sci, 2011. 56(12): p. 3405-20. 18. Thrift, A.P., et al., Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. J Natl Cancer Inst, 2014. 106(11). 19. Kubo, A., et al., Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut, 2013. 62(12): p. 1684-91. 20. Cook, M.B., et al., Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst, 2010. 102(17): p. 1344-53. 21. Lee, C.H., et al., Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer, 2005. 113(3): p. 475-82. 22. Yang, X., et al., Smoking and alcohol drinking in relation to the risk of esophageal squamous cell carcinoma: A population-based case-control study in China. Sci Rep, 2017. 7(1): p. 17249. 23. Tai, S.Y., et al., Cigarette smoking and alcohol drinking and esophageal cancer risk in Taiwanese women. World J Gastroenterol, 2010. 16(12): p. 1518-21. 24. Humans, I.W.G.o.t.E.o.C.R.t., Personal habits and indoor combustions. Volume 100 E. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum, 2012. 100(Pt E): p. 1-538. 25. Phukan, R.K., et al., Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India. Br J Cancer, 2001. 85(5): p. 661-7. 26. Boonyaphiphat, P., et al., Lifestyle habits and genetic susceptibility and the risk of esophageal cancer in the Thai population. Cancer Lett, 2002. 186(2): p. 193-9. 27. Wu, M.T., et al., Risk of betel chewing for oesophageal cancer in Taiwan. Br J Cancer, 2001. 85(5): p. 658-60. 28. Chang-Claude, J., et al., Familial aggregation of oesophageal cancer in a high incidence area in China. Int J Epidemiol, 1997. 26(6): p. 1159-65. 29. Li, J.Y., et al., A case-control study of cancer of the esophagus and gastric cardia in Linxian. Int J Cancer, 1989. 43(5): p. 755-61. 30. Huang, J., et al., High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China. Carcinogenesis, 2000. 21(11): p. 2019-26. 31. Li, G., et al., Allelic loss on chromosome bands 13q11-q13 in esophageal squamous cell carcinoma. Genes Chromosomes Cancer, 2001. 31(4): p. 390-7. 32. Su, H., et al., Gene expression analysis of esophageal squamous cell carcinoma reveals consistent molecular profiles related to a family history of upper gastrointestinal cancer. Cancer Res, 2003. 63(14): p. 3872-6. 33. Qu, X., Q. Ben, and Y. Jiang, Consumption of red and processed meat and risk for esophageal squamous cell carcinoma based on a meta-analysis. Ann Epidemiol, 2013. 23(12): p. 762-770 e1. 34. Dar, N.A., et al., Poor oral hygiene and risk of esophageal squamous cell carcinoma in Kashmir. Br J Cancer, 2013. 109(5): p. 1367-72. 35. Liu, J., et al., Intake of fruit and vegetables and risk of esophageal squamous cell carcinoma: a meta-analysis of observational studies. Int J Cancer, 2013. 133(2): p. 473- 85. 36. Dar, N.A., et al., Socioeconomic status and esophageal squamous cell carcinoma risk in Kashmir, India. Cancer Sci, 2013. 104(9): p. 1231-6. 37. Cao, H.H., et al., A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. Oncotarget, 2015. 6(7): p. 5435-48. 38. Islami, F., et al., High-temperature beverages and foods and esophageal cancer risk--a systematic review. Int J Cancer, 2009. 125(3): p. 491-524. 39. Earlam, R. and J.R. Cunha-Melo, Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg, 1980. 67(6): p. 381-90. 40. Earlam, R. and J.R. Cunha-Melo, Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br J Surg, 1980. 67(7): p. 457-61. 41. Swisher, S.G., et al., Changes in the surgical management of esophageal cancer from 1970 to 1993. Am J Surg, 1995. 169(6): p. 609-14. 42. Ando, N., et al., Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg, 2000. 232(2): p. 225-32. 43. Leichman, L., et al., Combined preoperative chemotherapy and radiation therapy for cancer of the esophagus: the Wayne State University, Southwest Oncology group and Radiation Therapy Oncology Group experience. Semin Oncol, 1984. 11(2): p. 178-85. 44. Kelsen, D.P., et al., Combination chemotherapy of esophageal carcinoma using cisplatin, vindesine, and bleomycin. Cancer, 1982. 49(6): p. 1174-7. 45. Lokich, J.J., M. Shea, and J. Chaffey, Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. Cancer, 1987. 60(3): p. 275-9. 46. Nigro, N.D., et al., Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer, 1983. 51(10): p. 1826-9. 47. Cooper, J.S., et al., Chemoradiotherapy of locally advanced esophageal cancer: long- term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA, 1999. 281(17): p. 1623-7. 48. Herskovic, A., et al., Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med, 1992. 326(24): p. 1593-8. 49. Okuno, T., et al., Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol, 2007. 30(3): p. 252-7. 50. Xu, C. and S. Lin, Esophageal cancer: comparative effectiveness of treatment options. Comparative Effectiveness Research, 2016. 6: p. 1-12. 51. Chen, P.C., et al., Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer. Int J Radiat Oncol Biol Phys, 2012. 82(5): p. 1996-2003. 52. van Hagen, P., et al., Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012. 366(22): p. 2074-84. 53. Esmatabadi, M.J., et al., Therapeutic resistance and cancer recurrence mechanisms: Unfolding the story of tumour coming back. J Biosci, 2016. 41(3): p. 497-506. 54. Baker, F., et al., Adult cancer survivors: how are they faring? Cancer, 2005. 104(11 Suppl): p. 2565-76. 55. Hsu, P.K., et al., Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg, 2011. 15(4): p. 558-65. 56. Law, S.Y., M. Fok, and J. Wong, Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg, 1996. 83(1): p. 107-11. 57. Nakagawa, S., et al., Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg, 2004. 198(2): p. 205-11. 58. Sanchez-Pernaute, A., et al., Recurrence pattern of esophageal cancer after esophagectomy with two-field lymphadenectomy. Rev Esp Enferm Dig, 2003. 95(3): p. 197-201, 191-6. 59. Shimada, H., et al., Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery, 2003. 133(1): p. 24-31. 60. Bhansali, M.S., et al., Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg, 1997. 21(3): p. 275-81. 61. Kunisaki, C., et al., Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg, 2008. 12(5): p. 802-10. 62. Su, X.D., et al., Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma. J Thorac Dis, 2014. 6(7): p. 949-57. 63. Hamai, Y., et al., Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma. World J Surg, 2018. 42(7): p. 2190-2198. 64. Chen, W.W., et al., Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy. Anticancer Res, 2013. 33(9): p. 4123-8. 65. Ferlay, J., et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010. 127(12): p. 2893-917. 66. Voncken, F.E., et al., Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer? Dis Esophagus, 2014. 27(6): p. 552-9. 67. Lin, G., H. Liu, and J. Li, Pattern of recurrence and prognostic factors in patients with pT1-3 N0 esophageal squamous cell carcinoma after surgery: analysis of a single center experience. J Cardiothorac Surg, 2019. 14(1): p. 58. 68. Zhou, F., et al., Genetic variants of DNA repair genes predict the survival of patients with esophageal squamous cell cancer receiving platinum-based adjuvant chemotherapy. J Transl Med, 2016. 14(1): p. 154. 69. Peng, L., et al., CCGD-ESCC: A Comprehensive Database for Genetic Variants Associated with Esophageal Squamous Cell Carcinoma in Chinese Population. Genomics Proteomics Bioinformatics, 2018. 16(4): p. 262-268. 70. He, B., et al., MicroRNAs in esophageal cancer (review). Mol Med Rep, 2012. 6(3): p. 459-65. 71. Zhong, B., et al., Contribution of nestin positive esophageal squamous cancer cells on malignant proliferation, apoptosis, and poor prognosis. Cancer Cell Int, 2014. 14: p. 57. 72. Barker, H.E., et al., The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer, 2015. 15(7): p. 409-25. 73. Morrison, R., et al., Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol, 2011. 2011: p. 941876. 74. Beresford, M.J., G.D. Wilson, and A. Makris, Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res, 2006. 8(6): p. 216. 75. Mitra, A., L. Mishra, and S. Li, EMT, CTCs and CSCs in tumor relapse and drug- resistance. Oncotarget, 2015. 6(13): p. 10697-711. 76. Roy, S., et al., Role of beta-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma. Cell Oncol (Dordr), 2018. 41(2): p. 185-200. 77. Ahmad, A., Pathways to breast cancer recurrence. ISRN Oncol, 2013. 2013: p. 290568. 78. Cao, M.Q., et al., miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a. J Hematol Oncol, 2018. 11(1): p. 12. 79. Benoit, B. and C. Pous, MAPping the Wnt pathway to hepatocellular carcinoma recurrence. Gut, 2016. 65(9): p. 1397-400. 80. Chen, J., et al., The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/beta-catenin signalling pathway. Gut, 2016. 65(9): p. 1522-34. 81. Takanami, I., Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer, 2005. 5: p. 1. 82. Song, J.L., et al., microRNA regulation of Wnt signaling pathways in development and disease. Cell Signal, 2015. 27(7): p. 1380-91. 83. Majidinia, M., et al., Cross-regulation between Notch signaling pathway and miRNA machinery in cancer. DNA Repair (Amst), 2018. 66-67: p. 30-41. 84. Ferretti, E., et al., Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J, 2008. 27(19): p. 2616-27. 85. Shi, L., et al., MicroRNA-223 antagonizes angiogenesis by targeting beta1 integrin and preventing growth factor signaling in endothelial cells. Circ Res, 2013. 113(12): p.1320-30. 86. Wen, J., et al., The epithelial-mesenchymal transition phenotype of metastatic lymph nodes impacts the prognosis of esophageal squamous cell carcinoma patients. Oncotarget, 2016. 7(25): p. 37581-37588. 87. Kalluri, R. and E.G. Neilson, Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest, 2003. 112(12): p. 1776-84. 88. Pecina-Slaus, N., Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int, 2003. 3(1): p. 17. 89. Peinado, H., D. Olmeda, and A. Cano, Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer, 2007. 7(6): p. 415-28. 90. Polyak, K. and R.A. Weinberg, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer, 2009. 9(4): p. 265- 73. 91. Chaffer, C.L. and R.A. Weinberg, A perspective on cancer cell metastasis. Science, 2011. 331(6024): p. 1559-64. 92. Zhang, H., et al., Fractionated irradiation-induced EMT-like phenotype conferred radioresistance in esophageal squamous cell carcinoma. J Radiat Res, 2016. 57(4): p. 370- 80. 93. Vega, S., et al., Snail blocks the cell cycle and confers resistance to cell death. Genes Dev, 2004. 18(10): p. 1131-43. 94. Shi, Q., et al., Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy. Thorac Cancer, 2018. 9(7): p. 836-846. 95. Lau, M.C., et al., FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFkappaB-BMP Signaling Cross-talk. Cancer Res, 2017. 77(21): p. 5886-5899. 96. van Staalduinen, J., et al., Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene, 2018. 97. O'Brien, J., et al., Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne), 2018. 9: p. 402. 98. Rottiers, V. and A.M. Naar, MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol, 2012. 13(4): p. 239-50. 99. Miska, E.A., How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev, 2005. 15(5): p. 563-8. 100. Bueno, M.J. and M. Malumbres, MicroRNAs and the cell cycle. Biochim Biophys Acta, 2011. 1812(5): p. 592-601. 101. Ardekani, A.M. and M.M. Naeini, The Role of MicroRNAs in Human Diseases. Avicenna J Med Biotechnol, 2010. 2(4): p. 161-79. 102. Nguyen, T.A., et al., Functional Anatomy of the Human Microprocessor. Cell, 2015. 161(6): p. 1374-87. 103. Wu, K., et al., The Role of Exportin-5 in MicroRNA Biogenesis and Cancer. Genomics Proteomics Bioinformatics, 2018. 16(2): p. 120-126. 104. Tsutsumi, A., et al., Recognition of the pre-miRNA structure by Drosophila Dicer-1. Nat Struct Mol Biol, 2011. 18(10): p. 1153-8. 105. Lee, Y., et al., The role of PACT in the RNA silencing pathway. EMBO J, 2006. 25(3): p. 522-32. 106. Guo, L. and Z. Lu, The fate of miRNA* strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule? PLoS One, 2010. 5(6): p. e11387. 107. Lim, L.P., et al., Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 2005. 433(7027): p. 769-73. 108. Chendrimada, T.P., et al., TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature, 2005. 436(7051): p. 740-4. 109. Kim, Y. and V.N. Kim, MicroRNA factory: RISC assembly from precursor microRNAs. Mol Cell, 2012. 46(4): p. 384-6. 110. Nakanishi, K., Anatomy of RISC: how do small RNAs and chaperones activate Argonaute proteins? Wiley Interdiscip Rev RNA, 2016. 7(5): p. 637-60. 111. Gurtner, A., et al., Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer Res, 2016. 35: p. 45. 112. Calin, G.A., et al., Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A, 2004. 101(9): p. 2999-3004. 113. Calin, G.A., et al., Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A, 2002. 99(24): p. 15524-9. 114. Yan, M., et al., Dysregulated expression of dicer and drosha in breast cancer. Pathol Oncol Res, 2012. 18(2): p. 343-8. 115. Lin, S. and R.I. Gregory, MicroRNA biogenesis pathways in cancer. Nat Rev Cancer, 2015. 15(6): p. 321-33. 116. He, J., et al., MicroRNA biogenesis pathway genes polymorphisms and cancer risk: a systematic review and meta-analysis. PeerJ, 2016. 4: p. e2706. 117. Guo, Y., et al., Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res, 2008. 68(1): p. 26-33. 118. Zhao, Y., et al., microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer, 2013. 132(12): p. 2901-9. 119. Zhang, T., et al., The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond), 2011. 121(10): p. 437-47. 120. Kroh, E.M., et al., Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods, 2010. 50(4): p. 298- 301. 121. Cai, E.H., et al., Serum miR-21 expression in human esophageal squamous cell carcinomas. Asian Pac J Cancer Prev, 2012. 13(4): p. 1563-7. 122. Komatsu, S., et al., Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer, 2011. 105(1): p. 104-11. 123. Zhang, C., et al., Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem, 2010. 56(12): p. 1871-9. 124. Zhang, T., et al., MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. Mol Carcinog, 2013. 52(8): p. 581-90. 125. Lan, F.F., et al., Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A). Int J Cancer, 2011. 128(2): p. 319-31. 126. Takamizawa, J., et al., Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res, 2004. 64(11): p. 3753-6. 127. Hirono, T., et al., MicroRNA-130b functions as an oncomiRNA in non-small cell lung cancer by targeting tissue inhibitor of metalloproteinase-2. Sci Rep, 2019. 9(1): p. 6956. 128. Frankel, L.B., et al., Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem, 2008. 283(2): p. 1026- 33. 129. Li, T., et al., MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun, 2009. 383(3): p. 280-5. 130. Wang, N., et al., MiR-21 down-regulation suppresses cell growth, invasion and induces cell apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal carcinoma. Dig Dis Sci, 2013. 58(7): p. 1863-70. 131. Ma, W.J., et al., Role of microRNA-21 and effect on PTEN in Kazakh's esophageal squamous cell carcinoma. Mol Biol Rep, 2011. 38(5): p. 3253-60. 132. Hiyoshi, Y., et al., MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res, 2009. 15(6): p. 1915-22. 133. Tang, Y., Z. Li, and Z.X. Shi, [Mechanisms of the suppression of proliferation and invasion ability mediated by microRNA-147b in esophageal squamous cell carcinoma]. Zhonghua Yi Xue Za Zhi, 2018. 98(26): p. 2092-2098. 134. Chen, M., et al., Downregulation of microRNA-370 in esophageal squamous-cell carcinoma is associated with cancer progression and promotes cancer cell proliferation via upregulating PIN1. Gene, 2018. 661: p. 68-77. 135. Song, Y., et al., MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget, 2014. 5(22): p. 11669-80. 136. Harazono, Y., et al., miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One, 2013. 8(5): p. e62757. 137. Ma, T., et al., MicroRNA-30c functions as a tumor suppressor via targeting SNAI1 in esophageal squamous cell carcinoma. Biomed Pharmacother, 2018. 98: p. 680-686. 138. Wang, C., et al., miR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2. Br J Cancer, 2016. 115(12): p. 1548-1554. 139. Matsushima, K., et al., MicroRNAs and esophageal squamous cell carcinoma. Digestion, 2010. 82(3): p. 138-44. 140. Bhatia, V., et al., Epigenetic Silencing of miRNA-338-5p and miRNA-421 Drives SPINK1-Positive Prostate Cancer. Clin Cancer Res, 2019. 25(9): p. 2755-2768. 141. Akutsu, Y., et al., Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg, 2009. 33(5): p. 1002-9. 142. Sumpter, K., et al., Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer, 2005. 92(11): p. 1976-83. 143. Enzinger, P.C., D.H. Ilson, and D.P. Kelsen, Chemotherapy in esophageal cancer. Semin Oncol, 1999. 26(5 Suppl 15): p. 12-20. 144. Li, F., et al., Downregulation of microRNA-21 inhibited radiation-resistance of esophageal squamous cell carcinoma. Cancer Cell Int, 2018. 18: p. 39. 145. Hamano, R., et al., Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res, 2011. 17(9): p. 3029-38. 146. Hong, L., et al., The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg, 2010. 251(6): p. 1056-63. 147. Kang, M.H. and C.P. Reynolds, Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res, 2009. 15(4): p. 1126-32. 148. Huang, H.Z., et al., Up-regulation of microRNA-136 induces apoptosis and radiosensitivity of esophageal squamous cell carcinoma cells by inhibiting the expression of MUC1. Exp Mol Pathol, 2019: p. 104278. 149. Hummel, R., et al., Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg, 2011. 15(3): p. 429-38. 150. Zhang, J., et al., miR-106b promotes cell invasion and metastasis via PTEN mediated EMT in ESCC. Oncol Lett, 2018. 15(4): p. 4619-4626. 151. Qiao, G., et al., Effects of miR106b3p on cell proliferation and epithelialmesenchymal transition, and targeting of ZNRF3 in esophageal squamous cell carcinoma. Int J Mol Med, 2019. 43(4): p. 1817-1829. 152. Zhao, Y., et al., MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol, 2018. 53(2): p. 644-658. 153. Hosseini, P., et al., An efficient annotation and gene-expression derivation tool for Illumina Solexa datasets. BMC Res Notes, 2010. 3: p. 183. 154. Zhang, J., et al., PEAR: a fast and accurate Illumina Paired-End reAd mergeR. Bioinformatics, 2014. 30(5): p. 614-20. 155. Friedlander, M.R., et al., Discovering microRNAs from deep sequencing data using miRDeep. Nat Biotechnol, 2008. 26(4): p. 407-15. 156. Anders, S. and W. Huber, Differential expression analysis for sequence count data. Genome Biol, 2010. 11(10): p. R106. 157. Robinson, M.D., D.J. McCarthy, and G.K. Smyth, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 2010. 26(1): p. 139-40. 158. Kramer, M.F., Stem-loop RT-qPCR for miRNAs. Curr Protoc Mol Biol, 2011. Chapter 15: p. Unit 15 10. 159. Lau, P., et al., Identification of dynamically regulated microRNA and mRNA networks in developing oligodendrocytes. J Neurosci, 2008. 28(45): p. 11720-30. 160. Dugas, J.C., et al., Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and myelination. Neuron, 2010. 65(5): p. 597-611. 161. Zhao, X., et al., MicroRNA-mediated control of oligodendrocyte differentiation. Neuron, 2010. 65(5): p. 612-26. 162. Barik, S., An intronic microRNA silences genes that are functionally antagonistic to its host gene. Nucleic Acids Res, 2008. 36(16): p. 5232-41. 163. Chen, Y., et al., Plasma miR-15b-5p, miR-338-5p, and miR-764 as Biomarkers for Hepatocellular Carcinoma. Med Sci Monit, 2015. 21: p. 1864-71. 164. Yong, F.L., C.W. Law, and C.W. Wang, Potentiality of a triple microRNA classifier: miR- 193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer, 2013. 13: p. 280. 165. Lei, D., et al., MiR-338-5p suppresses proliferation, migration, invasion, and promote apoptosis of glioblastoma cells by directly targeting EFEMP1. Biomed Pharmacother, 2017. 89: p. 957-965. 166. Liu, D.Z., et al., MiR-338 suppresses cell proliferation and invasion by targeting CTBP2 in glioma. Cancer Biomark, 2017. 20(3): p. 289-297. 167. Zheng, X., et al., CtBP2 is an independent prognostic marker that promotes GLI1 induced epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget, 2015. 6(6): p. 3752-69. 168. Tong, D., et al., MECP2 promotes the growth of gastric cancer cells by suppressing miR-338-mediated antiproliferative effect. Oncotarget, 2016. 7(23): p. 34845-59. 169. Hu, C.P., et al., Biologic properties of three newly established human esophageal carcinoma cell lines. J Natl Cancer Inst, 1984. 72(3): p. 577-83. 170. Dasari, S. and P.B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol, 2014. 740: p. 364-78. 171. Lu, T.P., et al., miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS One, 2012. 7(8): p. e42390. 172. Kim, M.S., et al., Neurofilament heavy polypeptide regulates the Akt-beta-catenin pathway in human esophageal squamous cell carcinoma. PLoS One, 2010. 5(2): p. e9003. 173. Zhang, H.F., et al., Loss of miR-200b promotes invasion via activating the Kindlin- 2/integrin beta1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin- independent mechanism. Oncotarget, 2015. 6(30): p. 28949-60. 174. Kiriyama, K., et al., Expression and function of FERMT genes in colon carcinoma cells. Anticancer Res, 2013. 33(1): p. 167-73. 175. Kramer, A., et al., Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics, 2014. 30(4): p. 523-30. 176. Rodriguez, A., et al., Identification of mammalian microRNA host genes and transcription units. Genome Res, 2004. 14(10A): p. 1902-10. 177. Ju, J.A., et al., Identification of colorectal cancer recurrence-related microRNAs. Biomarkers and Genomic Medicine, 2012. 4(1-2): p. 19-20. 178. Ju, J.A.H., C. T., et al., Characterization of a colorectal cancer migration and autophagy-related microRNA miR-338-5p and its target gene PIK3C3. Biomarkers and Genomic Medicine 2013. 5(3): p. 74-78. 179. Lv, Q., et al., DEDD interacts with PI3KC3 to activate autophagy and attenuate epithelial-mesenchymal transition in human breast cancer. Cancer Res, 2012. 72(13): p. 3238-50. 180. Li, Y., et al., MiR-338-5p Promotes Glioma Cell Invasion by Regulating TSHZ3 and MMP2. Cell Mol Neurobiol, 2018. 38(3): p. 669-677. 181. Besse, A., et al., MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response. Tumour Biol, 2016. 37(6): p. 7719- 27. 182. Zhang, J., et al., Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines. PLoS One, 2013. 8(1): p. e54111. 183. Zhao, Y., et al., The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma. Signal Transduct Target Ther, 2018. 3: p. 3. 184. Xing, Z., et al., Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p. Cell Biosci, 2016. 6: p. 53. 185. Plaisier, C.L., M. Pan, and N.S. Baliga, A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res, 2012. 22(11): p. 2302-14. 186. Zhikui, G., et al., A case-control study on the risk of esophageal carcinoma and miR- 338 cluster. Carcinogenesis, Teratogenesis & Mutagenesis, 2016. 28(2): p. 107-110. 187. Park, M., et al., MiR-338-5p enhances the radiosensitivity of esophageal squamous cell carcinoma by inducing apoptosis through targeting survivin. Sci Rep, 2017. 7(1): p. 10932. 188. Zhan, J., et al., Opposite role of Kindlin-1 and Kindlin-2 in lung cancers. PLoS One, 2012. 7(11): p. e50313. 189. Wang, P., et al., Differential expression of Kindlin-1 and Kindlin-2 correlates with esophageal cancer progression and epidemiology. Sci China Life Sci, 2017. 60(11): p. 1214-1222. 190. Sossey-Alaoui, K., et al., Kindlin-2 Regulates the Growth of Breast Cancer Tumors by Activating CSF-1-Mediated Macrophage Infiltration. Cancer Res, 2017. 77(18): p. 5129- 5141. 191. Ou, Y.W., et al., Mig-2 attenuates cisplatin-induced apoptosis of human glioma cells in vitro through AKT/JNK and AKT/p38 signaling pathways. Acta Pharmacol Sin, 2014. 35(9): p. 1199-206. 192. Brakebusch, C. and R. Fassler, The integrin-actin connection, an eternal love affair. EMBO J, 2003. 22(10): p. 2324-33. 193. Shirley, L.A., et al., Integrin-linked kinase affects signaling pathways and migration in thyroid | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73867 | - |
dc.description.abstract | 食道癌東亞地區的男性中致死率排名第五的癌症。由於五年存活率低,許多團 隊都致力於發展更好的治療方法。雖然目前 CCRT 合併手術是最常用的方法,然 而能有效完全去除腫瘤的比例仍然相對較低,而對 CCRT 效果較差的病患則有較 高的復發率與較低的存活率。復發是造成癌症病患的主要原因之一,因此藉由了解 其中的基因調控能有助於癌症的治療。miRNA 在細胞中是重要的調控分子,並且 有研究指出能調控與復發相關的訊息傳遞路徑。因此在這個研究中,利用次世代定 序方式來分析在這群病患中,有復發以及沒有復發的病患的 miRNA 表現量。研究 中,我發現到 15 個有顯著差異的 miRNA,並且藉由細胞實驗方式驗證這些 miRNA 在食道癌細胞中扮演的功能。其中,miR-338-5p 是在復發的病患檢體中表現量較 低的 miRNA,並且在細胞株的分析中,表現量在癌細胞也比較低。接著,我進一 步利用 MTT assay、clonogenic assay、transwell assay 以及 cisplatin 的處理來觀察 miR-338-5p 對於細胞的生長、存活、爬行以及對抗癌藥物的敏感性的影響。此外 我也藉由預測軟體和生物晶片來篩選可能被 miR-338-5p 調控的基因。兩種方法所 篩出的 31 個基因中,FERMT2 在兩個食道癌的大數據中,都能看到其表現與 miR- 338-5p 呈現負相關,此外在 qPCR 與西方點墨法中,能看到 FERMT2 表現量在轉 染 miR-338-5p 的細胞株中有下降,因此進一步以 luciferase assay 研究,並發現 miR- 338-5p 能藉由直接結合 FERMT2 3’ UTR 來調控 FERMT2 的表現。為了瞭解 FERMT2 在細胞增生、爬行、以及抗藥能力中所扮演的角色,除了用 shRNA 降低 FERMT2 的表現外,也在轉染 miR-338-5p 的細胞株中將 FERMT2 大量表現,結果 可發現 FERMT2 能回復一些 miR-338-5p 造成的效應。路徑分析中也能發現,miR- 338-5p 可能藉由 FERMT2 調控 ILK 路徑來影響細胞增生、爬行、以及抗藥性。此 研究能幫助我們了解更多與食道癌復發相關的機制,並對於未來癌症治療方法的 發展有所貢獻。 | zh_TW |
dc.description.abstract | Esophageal cancer (EC) is the 5th of leading causes of cancer death among the male population in Eastern Asia. Due to the poor overall 5-year survival rate, effective treatment strategies are needed to improve the long-term survival rate. Although concurrent chemoradiotherapy (CCRT) is the most effective treatment, patients without complete remission still suffer from high recurrence and low survival rate. miRNAs are important gene regulators which also involved in recurrence related pathways. Therefore, I applied Next generation sequencing method to evaluate miRNA expression in recurrence and non-recurrence ESCC patients post CCRT. Fifteen differential expressed miRNAs were identified. Among these miRNAs, miR-338-5p was not only down- regulated in tumor tissue of recurrence patients, but had lower expression level in ESCC cells than normal cells. To understand functions of miR-338-5p, I transfected miR-338- 5p mimic into the ESCC cells (CE-81T), and the results showed that miR-338-5p mimic reduced cell proliferation, survival, migration, and enhanced drug toxicity. Then miR- 338-5p potential target genes were identified utilizing microarray and prediction tools. There were 31 genes with 1.5-fold down-regulation in the miR-338-5p mimic transfected cells. Among these genes, FERMT2 was chosen for further study because it involved in integrin-linked protein kinase (ILK) signaling pathway that was significantly affected by miR-338-5p mimic transfection. In addition, to silence FERMT2 was similar to miR-338- 5p mimic transfection decreasing cell proliferation, survival, migration, and drug resistance. Restoration experiments showed overexpressed FERMT2 rescued the effect of miR-338-5p. This thesis demonstrates that miR-338-5p expression may play a critical role in preventing ESCC recurrence through repressing ILK pathway. My finding proposed that miR-338-5p may be a novel diagnosis marker for the estimation of ESCC recurrence risk, as well as a potential therapeutic component for ESCC treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T08:12:19Z (GMT). No. of bitstreams: 1 ntu-108-D00b48010-1.pdf: 8739546 bytes, checksum: bda462e29b8073dc6d75cc2ddbaa9bee (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員審定書 II
ACKNOWLEDGEMENT III 中文摘要 IV ABSTRACT V CONTENTS VII FIGURE LIST XI ABBREVIATIONS XIV CHAPTER 1. LITERATURE REVIEW 1 1.1 Esophageal cancer 1 1.1.1 Epidemiology 1 1.1.2 The risk factors of EAC 3 1.1.3 The risk factors of ESCC 5 1.1.4 The medical treatment 6 1.2 Recurrence of ESCC 7 1.2.1 Recurrence related pathways 8 1.2.2 Epithelial-mesenchymal transition (EMT) 9 1.3 MicroRNAs (miRNAs) 11 1.3.1 The biogenesis of miRNAs 12 1.3.2 The roles of miRNAs in ESCC 13 1.3.3 The roles of miRNAs in ESCC metastasis 15 1.3.4 The roles of miRNAs in ESCC treatment resistance 16 1.4 Motivation for this thesis 17 Aim1: Identify the potential recurrence-related miRNAs, and investigate their effects on cell proliferation, migration, and drug resistance. 18 Aim2: Identify the target genes of the recurrence-related miRNAs and study the effects on cell proliferation, migration, and drug resistance. 18 Aim3: Reveal potential ESCC recurrence-associated pathways that may be affected by the recurrence-related miRNAs 18 CHAPTER 2. MATERIALS AND METHODS 19 2.1 Experimental design 19 2.2 Sample collection 19 2.3 RNA extraction 20 2.4 Sample library and NGS data processing 20 2.5 Genomic DNA extraction 21 2.6 MiRNA expression constructs 21 2.7 Cell culture 21 2.8 miRNA real time PCR 22 2.9 Reverse-transcription and real time PCR 23 2.10 miRNA mimic transfection 24 2.11 MTT assay 24 2.12 Clonogenic assay 25 2.13 Transwell assay 25 2.14 Drug sensitivity assay 25 2.15 Microarray screening and pathway analysis 26 2.16 RNA-seq data analysis 26 2.17 Microarray data analysis 27 2.18 Western blot 27 2.19 Luciferase assay 27 2.20 shRNA virus package and infection 28 2.21 FERMT2 over-expression construct 28 2.22 Statistics 29 CHAPTER 3. RESULTS 30 3.1 Sequencing data analysis 30 3.2 Differentially expressed miRNAs in ESCC samples 30 3.3 Pre-examine the functional assays of potential recurrence related miRNAs by miRNA expression system 31 3.4 The functions of miR-338-5p in ESCC 31 3.4.1 miR-338-5p is down-regulated in ESCC cell lines 32 3.4.2 miR-338-5p inhibits the growth of CE-81T cells 32 3.4.3 miR-338-5p represses cell migration of CE-81T cells 33 3.4.4 miR-338-5p decreases drug resistance in CE-81T cells 33 3.5 Identification of the target genes of miR-338-5p 34 3.5.1 In silico prediction of the target genes of miR-338-5p 34 3.5.2 Potential target genes were down-regulated after miR- 338-5p transfection in CE-81T cells. 34 3.5.3 Correlation analysis of miR-338-5p expression and its potential target genes. 34 3.5.4 miR-338-5p directly binds on the 3’UTR of FERMT2 35 3.6 FERMT2 knockdown decreases cell proliferation, migration, and cisplatin resistance in CE-81T cells 36 3.6.1 Silencing of FERMT2 repressed cell growth 36 3.6.2 Silencing of FERMT2 repressed cell migration 36 3.6.3 Silencing of FERMT2 repressed drug resistance 37 3.6.4 The effects of overexpressed FERMT2 in miR-338-5p transfected CE-81T cells 37 3.7 miR-338-5p affects the ILK pathway via targeting FERMT2 38 3.8 Summary 39 CHAPTER 4. DISCUSSION 40 4.1 The novelty and significance of this thesis 40 4.2 The roles of miR-338-5p in ESCC 40 4.3 The roles of FERMT2 in ESCC 42 4.4 miR-338-5p may repress ILK signaling pathway in ESCC 43 4.5 FERMT2 can be regulated by miR-338-5p in KYSE series cell lines 45 4.6 The position 608 to 613 of FERMT2 3UTR is important for miR-338-5p binding 46 4.7 Limitations 46 4.8 Future works 47 TABLES 48 FIGURES 54 REFERENCES 76 APPENDIX 97 | |
dc.language.iso | en | |
dc.title | 探討與食道鱗狀細胞癌相關之miRNAs在細胞增生、爬行、以及抗藥性所扮演的角色 | zh_TW |
dc.title | To study the role of recurrence-related miRNAs on cell proliferation, migration, and drug resistance in esophageal squamous cell carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 莊曜宇,賴亮全,李章銘,李宣書 | |
dc.subject.keyword | 微小核醣核酸,miR-338-5p,食道鱗狀細胞癌,癌症復發,FERMT2,ILK訊息傳遞路徑, | zh_TW |
dc.subject.keyword | microRNA,miR-338-5p,esophageal squamous cell carcinoma,cancer recurrence,FERMT2,Integrin-linked kinase signaling, | en |
dc.relation.page | 96 | |
dc.identifier.doi | 10.6342/NTU201902859 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-15 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 基因體與系統生物學學位學程 | zh_TW |
顯示於系所單位: | 基因體與系統生物學學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 8.53 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。